| 000 | 01114 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250514073520.0 | ||
| 264 | 0 | _c20030829 | |
| 008 | 200308s 0 0 eng d | ||
| 022 | _a1389-4501 | ||
| 024 | 7 |
_a10.2174/1389450033490966 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStentz, Frankie B | |
| 245 | 0 | 0 |
_aActivated T lymphocytes in Type 2 diabetes: implications from in vitro studies. _h[electronic resource] |
| 260 |
_bCurrent drug targets _cAug 2003 |
||
| 300 |
_a493-503 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aLymphocyte Activation _ximmunology |
| 650 | 0 | 4 |
_aReceptor, IGF Type 1 _xbiosynthesis |
| 650 | 0 | 4 |
_aReceptor, Insulin _xbiosynthesis |
| 650 | 0 | 4 |
_aReceptors, Interleukin-2 _xbiosynthesis |
| 650 | 0 | 4 |
_aT-Lymphocytes _ximmunology |
| 700 | 1 | _aKitabchi, Abbas E | |
| 773 | 0 |
_tCurrent drug targets _gvol. 4 _gno. 6 _gp. 493-503 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1389450033490966 _zAvailable from publisher's website |
| 999 |
_c12644499 _d12644499 |
||